Antihemophilic Factor/von Willebrand Factor Complex (Human)

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Haemate, Immunate, Wilate; Belgium: Haemate, Wilate; Bulgaria: Immunate; Cyprus: Dried Factor VIII 8Y, Immunate; Czech Republic: Haemate, Immunate; Denmark: Haemate, Wilnativ; Estonia: Immunate, Wilate; Finland: Haemate, Wilate; France: Wistart; Germany: Haemate, Immunate, Wilate; Greece: Haemate, Immunate; Latvia: Dried Factor VIII Fraction 8Y, Immunate; Lithuania: Immunate; Malta: Dried Factor VIII Fraction, Immunate; Netherlands: Alphanate, Haemate, Immunate, Wilate; Poland: Haemate, Immunate; Portugal: Haemate, Immunate, Wilate; Romania: Haemate, Immunate; Slovakia: Haemate, Immunate, Wilate; Slovenia: Haemate; Spain: Haemate; Sweden: Immunate; UK: Alphanate, Dried Factor VIII Fraction type 8Y, Haemate, Optivate, Wilate.

North America

Canada: Humate, Wilate; USA: Alphanate, Humate.

Latin America

Argentina: Optivate; Brazil: Haemate; Mexico: Optivate.

Drug combinations


Pharmacologic Category

Antihemorrhagic Agents; Hemostatics. (ATC-Code: B02BD06).

Mechanism of action

Replacement of endogenous factor VIII and vWF in patients with hemophilia or von Willebrand disease. Factor VIII in conjunction with activated factor IX, activates factor X which converts prothrombin to thrombin and fibrinogen to fibrin. vWF promotes platelet aggregation and adhesion to damaged vascular endothelium and acts as a stabilizing carrier protein for factor VIII.

Therapeutic use

Prevention and treatment of hemorrhagic episodes in hemophilia A or acquired factor VIII deficiency. Prophylaxis in patients with von Willebrand disease when desmopressin is either ineffective or contraindicated. Treatment of spontaneous or trauma-induced bleeding, as well as prevention of excessive bleeding during and after surgery, in patients with von Willebrand disease where use of desmopressin is known or suspected to be inadequate.

Pregnancy and lactiation implications

Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women. Use with caution during lactation.

Unlabeled use


History of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor formulations. Hypersensitivity to any component of the formulation.

Warnings and precautions

Might cause development of factor VIII antibodies. Risk of thromboembolic events. Possible anemia and intravascular hemolysis in patients with blood groups A, B, and AB when large or frequently repeated doses are administered (contains trace amounts of blood groups A and B isohemagglutinins). Product of human plasma (may contain infectious agents).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart